Sylvia Ma

发表

Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors.

Abran Q. Costales, S. Ramurthy, S. Subramanian, 2008, Journal of medicinal chemistry.

Inhibition of prenylated KRAS in a lipid environment

Charles A. Wartchow, W. Jahnke, E. Fang, 2017, PloS one.

Design and synthesis of 5,6-fused heterocyclic amides as Raf kinase inhibitors.

Abran Q. Costales, S. Ramurthy, S. Subramanian, 2011, Bioorganic & medicinal chemistry letters.

4-(Aminoalkylamino)-3-benzimidazole-quinolinones as potent CHK-1 inhibitors.

Z. Ni, D. Bussiere, S. Ramurthy, 2006, Bioorganic & medicinal chemistry letters.

Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor.

D. Fabbro, W. Jahnke, G. Rummel, 2015, ACS medicinal chemistry letters.

Discovery and Optimization of DNA Gyrase and Topoisomerase IV Inhibitors with Potent Activity against Fluoroquinolone-Resistant Gram-Positive Bacteria.

Sarah L. Williams, D. Bussiere, X. Ling, 2021, Journal of medicinal chemistry.

Design and structure-activity relationship of heterocyclic analogs of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones as inhibitors of receptor tyrosine kinases.

M. Wiesmann, D. Bussiere, C. Shafer, 2006, Bioorganic & medicinal chemistry letters.

Discovery of 2-pyrimidyl-5-amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies.

E. Fang, Sylvia Ma, J. Murray, 2006, Bioorganic & medicinal chemistry letters.

Rationally Designed PI3Kα Mutants to Mimic ATR and Their Use to Understand Binding Specificity of ATR Inhibitors.

D. Bussiere, Yipin Lu, Li Zhang, 2017, Journal of molecular biology.

Design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases.

M. Wiesmann, C. Shafer, J. Jansen, 2006, Bioorganic & medicinal chemistry letters.

Topoisomerase Inhibitors Addressing Fluoroquinolone Resistance in Gram-Negative Bacteria.

Sarah L. Williams, D. Bussiere, Sylvia Ma, 2020, Journal of medicinal chemistry.

3-Benzimidazol-2-yl-1H-indazoles as potent c-ABL inhibitors.

C. Shafer, J. Jansen, Sylvia Ma, 2006, Bioorganic & medicinal chemistry letters.

CHIR-124, a Novel Potent Inhibitor of Chk1, Potentiates the Cytotoxicity of Topoisomerase I Poisons In vitro and In vivo

E. Moler, G. Schwartz, M. Embry, 2007, Clinical Cancer Research.

Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo.

Kirk W. Johnson, Sylvia Ma, J. Nuss, 2003, Diabetes.

Two Distinct Mechanisms of Inhibition of LpxA Acyltransferase Essential for Lipopolysaccharide Biosynthesis.

S. Subramanian, E. Ornelas, Sylvia Ma, 2020, Journal of the American Chemical Society.

Two distinct mechanisms of small molecule inhibition of LpxA acyltransferase essential for lipopolysaccharide biosynthesis

C. Ho, M. Li, S. Subramanian, 2019, bioRxiv.

In Vitro and In Vivo Properties of CUO246, a Novel Bacterial DNA Gyrase/Topoisomerase IV Inhibitor

Sylvia Ma, J. Leeds, C. Dean, 2022, Antimicrobial agents and chemotherapy.

Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers.

M. P. Dillon, Mallika Singh, E. Lees, 2017, Journal of medicinal chemistry.

Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers.

M. P. Dillon, Mallika Singh, E. Lees, 2017, Journal of medicinal chemistry.